Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... today announced that it will report its 2013 first quarter earnings on ... Ed Borkowski , CFO, will host an analyst and ... To participate in the conference call within the U.S. and ... conference call outside the U.S. and Canada , dial ... Participants should dial in 10 minutes prior to the start of the ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... , May 17, 2013 Oramed ... of oral drug delivery systems, announced today that the ... the Company,s Investigational New Drug application(IND) for ORMD-0801, its ... to have the FDA clearance to proceed," stated ... upcoming trial is a major milestone for Oramed and ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... Male Hypogonadism, LEXINGTON, Mass., Aug. 28 ... that it has submitted,a New Drug Application (NDA) ... approval for NEBIDO(R) (testosterone undecanoate) intramuscular,injection, a long-acting ... and secondary hypogonadism. Each 1000 mg injection of,NEBIDO ...
... Corporation,(Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen ... dosing in a Phase I/II clinical,trial evaluating belinostat ... the anthracycline idarubicin for the,treatment of Acute Myeloid ... sites in the European Union. Patients under ...
Cached Medicine Technology:Indevus Announces Submission of New Drug Application 2Indevus Announces Submission of New Drug Application 3Indevus Announces Submission of New Drug Application 4Indevus Announces Submission of New Drug Application 5Indevus Announces Submission of New Drug Application 6CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 2CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 3CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 4CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 5CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 6
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... 19, 2013 The Pradaxa lawyers at ... was recently convened for hundreds of Pradaxa bleeding ... underway in U.S. District Court, Southern District of Illinois. ... on May 14th, the Conference addressed the status of ... during the Conference that Defendants submitted a list of ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... Raton, FL (PRWEB) May 19, 2013 ... launched the website YazSideEffects.com in a concerted effort to ... of the combination birth control drugs Yaz, Yasmin & ... offers a wealth of information on the notorious birth ... lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin & ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... and the good fats in Omega-3 fatty acids help new ... the issue of the International Breastfeeding Journal. ... affecting anywhere from 10 percent to 20 percent of postpartum ... as high as 40 percent or 50 percent. Since depression ...
... the home clearly raise the risk of the allergic sensitisation ... older children , however, the influence of the environment at ... This is the conclusion reached by scientists from the GSF ... ,The study published by Chih-Mei Chen et ...
... New Jersey The nations publicized gay governor, James E. McGreevy ... he has managed to be in the news for ... and has become an Episcopalian. ,Former Gov. James E. ... officially inducted into the Episcopal religion on Sunday at St. ...
... here have developed a device that can enable the blind to ... it costs Rs.2,000-3,000 and it reads texts through an embedded system ... ,Right now it can only read text, but ... ,The Agra College team that took six months to ...
... to the information furnished by Indira Gandhi National Open ... of Parliament/State legislature or deemed to be university ... of norms and guidelines laid down by the Distance ... its meeting held on March 23, 2007 had resolved ...
... state representatives from 105 countries met Friday to formally adopt ... impacts of global warming after five days of heated debate ... discussions ended at 3:30 a.m. Friday," said Carloa Traverso Saibante, ... (IPCC). ,Once the IPCC report is formally adopted, ...
Cached Medicine News:Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Climate Talks Reach Consensus in Bangkok 2
... Revolutions start with small things. The ... one of the trailblazers of the ... the,trend towards ever smaller access and ... operation site. ,The HiLAN XS motor ...
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
... The basic frame, consisting of one part only, ... fixations of highly compressed Polyamide may be rotated ... to all head sizes and shapes, as well. ... frame far enough in caudal direction, which is ...
Medicine Products: